

FORM 5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Form 3 Holdings Reported.

Form 4 Transactions Reported.

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0362
Estimated average burden hours per response:	1.0

1. Name and Address of Reporting Person* <u>Savitr Capital, LLC</u> (Last) (First) (Middle) <u>ONE MARKET PLAZA</u> <u>STEUART TOWER, STE.1400</u> (Street) <u>SAN FRANCISCO CA 94105</u> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>HERON THERAPEUTICS, INC. /DE/ [HRTX]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title below) <input checked="" type="checkbox"/> Other (specify below) <u>Exiting 10% holder</u>
	3. Statement for Issuer's Fiscal Year Ended (Month/Day/Year) <u>12/31/2014</u>	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned at end of Issuer's Fiscal Year (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
				Amount	(A) or (D)	Price			
Heron Therapeutics Common Stock	03/12/2014		S4 ⁽¹⁾	9,000	D	\$14.4677	1,712,366	D	
Heron Therapeutics Common Stock	03/13/2014		S4 ⁽¹⁾	4,000	D	\$14.5693	1,712,366	D	
Heron Therapeutics Common Stock	03/14/2014		S4 ⁽¹⁾	2,000	D	\$14.8562	1,712,366	D	
Heron Therapeutics Common Stock	03/18/2014		S4 ⁽¹⁾	10,000	D	\$15.1757	1,712,366	D	
Heron Therapeutics Common Stock	03/19/2014		S4 ⁽¹⁾	10,000	D	\$15.5307	1,712,366	D	
Heron Therapeutics Common Stock	03/20/2014		S4 ⁽¹⁾	5,000	D	\$15.5801	1,712,366	D	
Heron Therapeutics Common Stock	03/21/2014		S4 ⁽¹⁾	3,000	D	\$15.3038	1,712,366	D	
Heron Therapeutics Common Stock	03/25/2014		S4 ⁽¹⁾	4,000	D	\$14.1001	1,712,366	D	
Heron Therapeutics Common Stock	03/27/2014		S4 ⁽¹⁾	1,000	D	\$14.33	1,712,366	D	
Heron Therapeutics Common Stock	06/24/2014		S4 ⁽¹⁾	19,147	D	\$12.8187	1,712,366	D	
Heron Therapeutics Common Stock	07/03/2014		S4 ⁽¹⁾	3,300	D	\$12.4502	1,712,366	D	
Heron Therapeutics Common Stock	07/25/2014		S4 ⁽¹⁾	3,000	D	\$9.0317	1,712,366	D	
Heron Therapeutics Common Stock	07/29/2014		S4 ⁽¹⁾	4,000	D	\$9.097	1,712,366	D	
Heron Therapeutics Common Stock	07/30/2014		S4 ⁽¹⁾	3,000	D	\$9.1967	1,712,366	D	
Heron Therapeutics Common Stock	07/31/2014		S4 ⁽¹⁾	1,000	D	\$9.2848	1,712,366	D	
Heron Therapeutics Common Stock	09/19/2014		S4 ⁽¹⁾	10	D	\$9.1	1,712,366	D	
Heron Therapeutics Common Stock	09/24/2014		S4 ⁽¹⁾	1,000	D	\$8.55	1,712,366	D	
Heron Therapeutics Common Stock	09/26/2014		S4 ⁽¹⁾	1,000	D	\$8.52	1,712,366	D	
Heron Therapeutics Common Stock	09/30/2014		S4 ⁽¹⁾	1,000	D	\$8.4005	1,712,366	D	
Heron Therapeutics Common Stock	10/24/2014		S4 ⁽¹⁾	1,000	D	\$7.42	1,712,366	D	
Heron Therapeutics Common Stock	12/16/2014		S4 ⁽¹⁾	3,700	D	\$9.3573	1,712,366	D	
Heron Therapeutics Common Stock	12/17/2014		S4 ⁽¹⁾	1,000	D	\$9.24	1,712,366	D	
Heron Therapeutics Common Stock	12/19/2014		S4 ⁽¹⁾	1,000	D	\$9.33	1,712,366	D	
Heron Therapeutics Common Stock	12/22/2014		S4 ⁽¹⁾	2,000	D	\$9.6515	1,712,366	D	
Heron Therapeutics Common Stock	12/23/2014		S4 ⁽¹⁾	1,000	D	\$9.8	1,712,366	D	
Heron Therapeutics Common Stock							1,712,366	D	
Heron Therapeutics Common Stock	09/29/2014		S4 ⁽¹⁾	3,000	D	\$8.7653	1,712,366	D	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					(A)	(D)	Date Exercisable	Expiration Date					

Explanation of Responses:

1. 4

Andrew R. Midler, Managing Member 02/12/2015

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.